---

---

tags : Positive    crawled time : 16:20   

save search

---

Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome
Published: 2024-04-07 (Crawled : 16:20) - prnewswire.com
IONS | $41.08 0.98% 0.97% 670K |

Health Technology

| Email alert Add to watchlist
positive for results study

---

Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
Published: 2024-04-06 (Crawled : 16:20) - globenewswire.com
OCUL | News | $5.075 -2.78% -2.86% 3.7M |

Health Technology

| Email alert Add to watchlist
glaucoma ocular positive meeting

---

Jasper Therapeutics Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation at ASH 2023
Published: 2023-12-10 (Crawled : 16:20) - globenewswire.com
JSPR | $22.27 3.15% 3.05% 86K |

| Email alert Add to watchlist
presentation positive cell aml therapeutics results study

---

Vera Therapeutics Presents Positive Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria in Majority of Patients at the American Society of Nephrology Kidney Week 2023
Published: 2023-11-04 (Crawled : 16:20) - globenewswire.com
VERA | $39.07 2.82% 2.74% 710K |

Professional, Scientific, and T...

| Email alert Add to watchlist
kidney origin positive week therapeutics study

---

4DMT Presents Additional Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial in Patients with Wet AMD at ASRS 2023
Published: 2023-07-29 (Crawled : 16:20) - globenewswire.com
FDMT M | $26.43 4.67% 4.46% 480K |

Health Technology

| Email alert Add to watchlist
prism positive trial

---

MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa
Published: 2023-06-25 (Crawled : 16:20) - globenewswire.com
MLTX | $41.14 -2.49% -2.55% 280K |

| Email alert Add to watchlist
SNYNF | News | $92.7 -2.18% 600K |

Health Technology

| Email alert Add to watchlist
SNY | News | $47.125 1.78% 1.75% 2.1M |

Health Technology

| Email alert Add to watchlist
nanobody positive results milestone phase 2

---

Vera Therapeutics Announces Positive Week 36 Efficacy and Safety Results of Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN in Late-Breaking Presentation at 60th European Renal Association (ERA) Congress
Published: 2023-06-17 (Crawled : 16:20) - globenewswire.com
VERA | $39.07 2.82% 2.74% 710K |

Professional, Scientific, and T...

| Email alert Add to watchlist
association renal presentation origin positive week trial therapeutics results igan

---

Intellia Therapeutics Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE)
Published: 2023-06-11 (Crawled : 16:20) - globenewswire.com
NTLA | $21.85 1.3% 1.28% 1M |

Health Technology

| Email alert Add to watchlist
ntla-2002 crispr positive treatment therapeutics study

---

Celldex Therapeutics Presents Positive Data from Barzolvolimab Chronic Urticaria Program at EAACI 2023
Published: 2023-06-10 (Crawled : 16:20) - globenewswire.com
CLDX | $38.83 2.24% 2.19% 550K |

Health Technology

| Email alert Add to watchlist
urticaria positive program therapeutics

---

Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse™ Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastatic HPV-associated Cancers
Published: 2023-06-03 (Crawled : 16:20) - prnewswire.com
PGEN | $1.38 3.76% 3.62% 890K |

Health Technology

| Email alert Add to watchlist
prgn-2009 positive immunotherapy

---

Elicio Therapeutics Announces Positive Interim Data from the Phase 1 Study of an Investigational Therapeutic Cancer Immunotherapy, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at the ASCO Annual Meeting
Published: 2023-06-03 (Crawled : 16:20) - globenewswire.com
ELTX | $9.72 15.71% 13.58% 68K |

| Email alert Add to watchlist
eli-002 asco positive cancer pancreatic risk meeting therapeutics study

---

IDEAYA Announces Positive Interim Phase 2 Data for Darovasertib and Crizotinib Combination and Successful FDA Type C Meeting on Registrational Trial Design for Accelerated Approval in First-Line Metastatic Uveal Melanoma
Published: 2023-04-23 (Crawled : 16:20) - prnewswire.com
IDYA | News | $37.52 1.05% 1.04% 780K |

Health Technology

| Email alert Add to watchlist
fda melanoma approval positive meeting trial

---

Cytokinetics Presents Positive Results From Cohort 4 of REDWOOD-HCM and Long-Term Results From FOREST-HCM at the American College of Cardiology 72nd Annual Scientific Session
Published: 2023-03-04 (Crawled : 16:20) - globenewswire.com
CYTK | $66.35 -1.78% -1.81% 1.2M |

Health Technology

| Email alert Add to watchlist
cardiology positive results

---

Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at AAAAI 2023
Published: 2023-02-26 (Crawled : 16:20) - globenewswire.com
CLDX | $38.83 2.24% 2.19% 550K |

Health Technology

| Email alert Add to watchlist
urticaria therapeutics positive study

---

Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED)
Published: 2023-01-08 (Crawled : 16:20) - globenewswire.com
VRDN | $14.28 -2.19% -2.24% 810K |

Health Care and Social Assistan...

| Email alert Add to watchlist
vrdn-001 ongoing thyroid disease eye trial positive phase 1

---

I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022
Published: 2022-09-10 (Crawled : 16:20) - prnewswire.com
IMAB | $1.8 0.0% 140K |

Health Technology

| Email alert Add to watchlist
risk positive phase 2

---

Ionis announces presentation of positive Phase 2b data for chronic hepatitis B treatment at the EASL International Liver Congress™
Published: 2022-06-25 (Crawled : 16:20) - prnewswire.com
IONS | $41.08 0.98% 0.97% 670K |

Health Technology

| Email alert Add to watchlist
treatment hepatitis liver presentation positive international phase 2b chronic hepatitis b

---

CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress
Published: 2022-06-11 (Crawled : 16:20) - globenewswire.com
CRSP | News M | $55.7 1.18% 1.17% 1M |

Health Technology

| Email alert Add to watchlist
ctx130 crispr trial therapeutics positive results phase 1

---

HOOKIPA announces positive Phase 1 data and Phase 2 plans for HB-200 program for the treatment of advanced head and neck cancers at ASCO
Published: 2022-06-05 (Crawled : 16:20) - globenewswire.com
HOOK | $0.7125 -2.8% -2.88% 850K |

Health Technology

| Email alert Add to watchlist
hb-200 treatment program asco positive phase 1 phase 2

---

Everest Medicines' Licensing Partner Gilead Sciences Announces Positive Results from Phase 3 TROPiCS-02 Study of Trodelvy® in Heavily Pre-treated HR+/HER2- Metastatic Breast Cancer Patients
Published: 2022-06-04 (Crawled : 16:20) - prnewswire.com
GILD | $66.95 0.29% 0.28% 5.6M |

Health Technology

| Email alert Add to watchlist
cs-02 trodelvy sciences positive results cancer breast cancer phase 3 her2- her2 metastatic breast cancer

---

Gainers vs Losers

75%

25%

Top 10 Gainers

MTTR | News M | $4.78 174.71% 63.6% 72M |

AGBA | $2.565 105.2% 51.27% 200M |

Finance

MLEC | $2.44 74.29% 42.62% 78M |

n/a

EDBL | News | $6.28 67.02% 40.13% 16M |

ATGL | $2.91 48.81% 32.8% 180K |

ZAPP | $0.2175 47.16% 32.05% 16M |

n/a

ONFO | $0.6075 38.38% 27.74% 7.3M |

n/a

VIVK | $1.48 38.32% 27.7% 530K |

Professional, Scientific, and T...

MNTS | $0.5 35.69% 26.3% 4.8M |

SDIG A | $3.635 35.13% 26.0% 1M |

---

Your saved searches

---